MAO A/HDAC-IN-1 

MAO A/HDAC-IN-1 is a dual?inhibitor?of monoamine oxidase A (MAO A) and HDAC. MAO A/HDAC-IN-1 can be used for glioma research^[1]. MAO A/HDAC-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

MAO A/HDAC-IN-1 (compound 15) increases histone H3 and α-tubulin acetylation and induce cell death via nonapoptotic mechanisms^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MAO A/HDAC-IN-1 (compound 15) reduces tumor size, reduced MAO A activity in brain and tumor tissues, and prolonged the survival^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

401.89

C₂₁H₂₄ClN₃O₃

3031466-56-2

ClC1=C(C=CC(NCC2=CC=C(C=C2)C(NO)=O)=C1)OCCCN(CC#C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Samir Mehndiratta, et al. N-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment. J Med Chem. 2022 Feb 10;65(3):2208-2224.  [Content Brief]